{
  "version": 1,
  "title": "PeptideIQ curated research sources",
  "publisher": "Vee the peptide company",
  "scope": "Five currently covered compound topics; not a complete literature feed.",
  "editorialDisclosure": "AI-assisted summaries. No named clinical reviewer, independent systematic review, or product verification claimed.",
  "entries": [
    {
      "topic": "BPC-157",
      "path": "/compounds/bpc-157",
      "aliases": [
        "BPC 157",
        "BPC157",
        "body protection compound-157"
      ],
      "context": "BPC-157 is a laboratory-made peptide made up of 15 amino acids. It appears in musculoskeletal and tissue-repair research, but research interest is not proof of a clinical benefit.",
      "source": {
        "title": "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review",
        "url": "https://pubmed.ncbi.nlm.nih.gov/40756949/",
        "publication": "HSS Journal, 2025",
        "evidence": "Systematic review; mostly animal studies",
        "summary": "Reviews proposed orthopedic uses and finds the evidence is largely preclinical.",
        "limitations": "A review cannot establish efficacy; human clinical evidence is limited."
      }
    },
    {
      "topic": "TB-500",
      "path": "/compounds/tb-500",
      "aliases": [
        "TB 500",
        "thymosin beta-4 research"
      ],
      "context": "TB-500 is a name used in research-market peptide listings associated with thymosin beta-4. A market name alone does not identify the exact sequence or formulation studied in a paper.",
      "source": {
        "title": "The effect of thymosin treatment of venous ulcers",
        "url": "https://pubmed.ncbi.nlm.nih.gov/20536470/",
        "publication": "Annals of the New York Academy of Sciences, 2010",
        "evidence": "Phase 2 placebo-controlled human study",
        "summary": "Tested topical full-length thymosin beta-4 for venous ulcers and reports a possible healing signal at one concentration.",
        "limitations": "Full-length topical thymosin beta-4 is not the same as products sold as TB-500."
      }
    },
    {
      "topic": "GHK-Cu",
      "path": "/compounds/ghk-cu",
      "aliases": [
        "GHK Cu",
        "copper tripeptide",
        "glycyl-L-histidyl-L-lysine copper"
      ],
      "context": "GHK-Cu is a copper complex of the tripeptide glycyl-L-histidyl-L-lysine. The library includes a human study of a specific topical gel used with standardized diabetic-ulcer wound care.",
      "source": {
        "title": "Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper",
        "url": "https://pubmed.ncbi.nlm.nih.gov/17147644/",
        "publication": "Wound Repair and Regeneration, 1994",
        "evidence": "Randomized placebo-controlled human study",
        "summary": "Reported greater diabetic ulcer closure with a topical GHK-Cu gel plus standard wound care.",
        "limitations": "Specific to one topical formulation and wound care; not evidence for other uses."
      }
    },
    {
      "topic": "Semaglutide",
      "path": "/compounds/semaglutide",
      "aliases": [
        "semaglutide research",
        "STEP 1",
        "GLP-1 receptor agonist"
      ],
      "context": "Semaglutide is a GLP-1 receptor agonist. The STEP 1 paper studied a defined semaglutide protocol with lifestyle intervention in adults with overweight or obesity.",
      "source": {
        "title": "Once-Weekly Semaglutide in Adults with Overweight or Obesity",
        "url": "https://pubmed.ncbi.nlm.nih.gov/33567185/",
        "publication": "The New England Journal of Medicine, 2021",
        "evidence": "Randomized clinical trial in adults",
        "summary": "The STEP 1 trial evaluated semaglutide with lifestyle intervention for weight management.",
        "limitations": "Applies to the studied population and supervised approved-drug protocol, not research-market products."
      }
    },
    {
      "topic": "Tirzepatide",
      "path": "/compounds/tirzepatide",
      "aliases": [
        "tirzepatide research",
        "SURMOUNT-1",
        "GIP and GLP-1 receptor agonist"
      ],
      "context": "Tirzepatide is a GIP and GLP-1 receptor agonist. SURMOUNT-1 investigated it in adults with obesity or overweight without diabetes under a defined clinical protocol.",
      "source": {
        "title": "Tirzepatide Once Weekly for the Treatment of Obesity",
        "url": "https://pubmed.ncbi.nlm.nih.gov/35658024/",
        "publication": "The New England Journal of Medicine, 2022",
        "evidence": "Randomized clinical trial in adults",
        "summary": "The SURMOUNT-1 trial studied tirzepatide for weight management in adults without diabetes.",
        "limitations": "Results apply to the trial population and protocol, not every group or product."
      }
    }
  ]
}